CO5150205A1 - Metodos de aumentar el volumen oseo que comprende administrar un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento - Google Patents

Metodos de aumentar el volumen oseo que comprende administrar un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento

Info

Publication number
CO5150205A1
CO5150205A1 CO00016009A CO00016009A CO5150205A1 CO 5150205 A1 CO5150205 A1 CO 5150205A1 CO 00016009 A CO00016009 A CO 00016009A CO 00016009 A CO00016009 A CO 00016009A CO 5150205 A1 CO5150205 A1 CO 5150205A1
Authority
CO
Colombia
Prior art keywords
agonist
selective
treatment
subject
requires
Prior art date
Application number
CO00016009A
Other languages
English (en)
Spanish (es)
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5150205A1 publication Critical patent/CO5150205A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO00016009A 1999-03-05 2000-03-06 Metodos de aumentar el volumen oseo que comprende administrar un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento CO5150205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
CO5150205A1 true CO5150205A1 (es) 2002-04-29

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00016009A CO5150205A1 (es) 1999-03-05 2000-03-06 Metodos de aumentar el volumen oseo que comprende administrar un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento

Country Status (10)

Country Link
EP (1) EP1158969A2 (fr)
JP (1) JP2002538105A (fr)
AU (1) AU3711900A (fr)
CA (1) CA2366755A1 (fr)
CO (1) CO5150205A1 (fr)
IL (1) IL145128A0 (fr)
NO (1) NO20014192L (fr)
NZ (1) NZ513828A (fr)
PE (1) PE20001552A1 (fr)
WO (1) WO2000051585A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878429B1 (fr) 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Préparation pour absorption transdermale
KR20090075864A (ko) 2006-10-26 2009-07-09 오노 야꾸힝 고교 가부시키가이샤 첨부제
EP2305304A4 (fr) 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine Immunostimulant comprenant l' agoniste ep1
CA2792161A1 (fr) * 2010-03-05 2011-09-09 University Of Rochester Inhibition d'ep1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
WO1992021350A1 (fr) * 1991-05-29 1992-12-10 Sepracor, Inc. Combinaison de medicaments anti-inflammatoires non steroidiens et de prostaglandines et leur utilisation
KR20010023840A (ko) * 1997-09-09 2001-03-26 데이비드 엠 모이어 비천연 선택성 ｆｐ 아고니스트를 이용한 골 부피 증가 방법
EP1121133A1 (fr) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methodes de stimulation de la formation osseuse
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
PE20001552A1 (es) 2001-01-30
JP2002538105A (ja) 2002-11-12
WO2000051585A2 (fr) 2000-09-08
WO2000051585A3 (fr) 2001-01-25
AU3711900A (en) 2000-09-21
CA2366755A1 (fr) 2000-09-08
NZ513828A (en) 2001-09-28
EP1158969A2 (fr) 2001-12-05
IL145128A0 (en) 2002-06-30
NO20014192D0 (no) 2001-08-29
NO20014192L (no) 2001-11-05

Similar Documents

Publication Publication Date Title
AU4935701A (en) Use of insulin for the treatment of cartilagenous disorders
CO5280216A1 (es) Tratamiento de la enfermendad neurodegenerativa
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
IS1724B (is) Aðferð við meðhöndlun á ígræðlingi úr málmi fyrirskurðaðgerð
CO5221115A1 (es) Nuevos compuestos fungicidas
EP1205154A3 (fr) Dispositif de plaque pour ostéosynthèse et méthode avec une plaque à extension
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
WO2004032988A3 (fr) Agents de couplage pour biomateriaux orthopediques
BR0114758A (pt) Inibidores do receptor ep4 para tratamento de artrite reumatóide
WO2001030264A3 (fr) Systeme de prothese de cheville
CO5271724A1 (es) Uso de agonistas de prostaglandinas para tratar la disfuncion erectil o la impotencia
BR9913705A (pt) Métodos de tratamento de mieloma múltiplo e reabsorção de tecido ósseo induzido por mieloma utilizando antagonistas de integrin
EP1173470A4 (fr) Traitement de troubles osseux a base d'adrenomedulline ou d'agonistes de l'adrenomedulline
CO5150205A1 (es) Metodos de aumentar el volumen oseo que comprende administrar un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento
CO5150178A1 (es) Bromohidrato de eletriptan monohidrato y procedimiento para su preparacion
HK1053053A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies.
GB2331301C (en) Galanin
CO5280195A1 (es) Combinaciones sinteticas de un antagonista de receptor de nk, y un analalogo estructural de gaba
WO2000012047A3 (fr) Stimulation du retour a des conditions de vie independantes au moyen d'un secretagogue d'hormone de croissance
Moroni et al. Fixation strength of tapered versus bicylindrical hydroxyapatite‐coated external fixation pins: An animal study
PT1152757E (pt) Inibidores de mmp no amolecimento do tecido conjuntivo
CO5140078A1 (es) Composicion y metodo para tratar enfermedades alergicas dades respiratorias que comprende combinaciones de antagonis tas de receptores de neuroquinina e histamina
CO5150204A1 (es) Metodo de aumentar el volumen oseo que comprende la administracion de un agonista fp selectivo que no ocurre naturalmente y un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento
BR0311292A (pt) Combinação de beta-bloqueador e bloqueador de receptor de angiotensina ii para prevenção secundária de infarto do miocárdio
BR9905648A (pt) Mediador de androgênio oticamente puro